CN106540237A - A kind of pharmaceutical composition for suppressing gastric cancer - Google Patents
A kind of pharmaceutical composition for suppressing gastric cancer Download PDFInfo
- Publication number
- CN106540237A CN106540237A CN201611134386.0A CN201611134386A CN106540237A CN 106540237 A CN106540237 A CN 106540237A CN 201611134386 A CN201611134386 A CN 201611134386A CN 106540237 A CN106540237 A CN 106540237A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- arborisidine
- pharmaceutical composition
- pimelautide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for suppressing gastric cancer, effective ingredient includes Arborisidine A, also including pimelautide.The present invention passes through Arborisidine A and pimelautide use in conjunction has good effect for preventing and treating gastric cancer.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for suppressing gastric cancer, belongs to pharmaceutical technology field.
Background technology
Gastric cancer ranks first in the various malignant tumor of China, and incidence gastric cancer has obvious region gender gap, in the west of China
North is evident as high with coastal region in east China incidence gastric cancer rate than southern area.The age is sent out well more than 50 years old, men and women's sickness rate it
Than for 2：1.The prognosis of gastric cancer is relevant with the pathological staging of gastric cancer, position, organization type, biological behaviour and remedy measures.
Gastric cancer is one of modal malignant tumor of gynecological.The suppression gastric cancer medicament for finding high-efficiency low-toxicity is important problem.
Arborisidine is a kind of monoterpenoid indole alkaloid of brand-new skeleton, is published in Arborisidine and first
Arbornamine, Two Monoterpenoid Indole Alkaloids with New Polycyclic Carbon-
Nitrogen Skeletons Derived from a Common Pericine Precursor。Org.Lett.,2016,18
(7),1618–1621。
It is found by the applicant that Arborisidine A and pimelautide synergy are suppressing gastric cancer to have good effect.
The content of the invention
For the problem that above-mentioned prior art is present, the present invention provides a kind of medicine for suppressing gastric cancer.
To achieve these goals, the technical solution used in the present invention is：A kind of medicine for suppressing gastric cancer, effectively into
Dividing includes Arborisidine A, and structural formula is as follows：
Effective ingredient includes also including pimelautide.
Calculate according to weight, Arborisidine A and pimelautide ratio are 1:1-20:1.
The a kind of of present invention offer is used for suppressing the medicine of gastric cancer comprising Arborisidine A, by Arborisidine
A and pimelautide use in conjunction, test result indicate that, Arborisidine A and pimelautide are 16:1-19:1 for suppression
Gastric cancer has good cooperative effect.
Specific embodiment
Described above is only the general introduction of technical solution of the present invention, in order to better understand the technological means of the present invention,
And can be practiced according to the content of description and ordinary skill in the art means, below the animal experiment example of the present invention is done
It is described in further detail.
Chinese:Pimelautide, No. CAS:The companies such as the happy Industrial Co., Ltd. of 78512-63-7, Shanghai Jin Jin have
Sell.
The preparation method of compound Arborisidine A involved in the present invention is referring to document：(Arborisidine and
Arbornamine, Two Monoterpenoid Indole Alkaloids with New Polycyclic Carbon-
Nitrogen Skeletons Derived from a Common Pericine Precursor。Org.Lett.,2016,18
(7),1618–1621)。
The test of pesticide effectiveness：
Modeling：Cleaning grade nude mouse, 22～28g of body weight, male, 27 DEG C～30 DEG C of animal housing's ambient temperature, humidity 35%
～45%.210 nude mouses are randomly divided into 21 groups, 10 per group, are divided into 20 groups of administration groups, one group of matched group.Nude mouse is subcutaneous
The foundation of Transplanted tumor model breaks up Wei-wei Decoction (MKN-45) from people is low, purchased from No.1 Military Medical Univ.'s cell centre.
RPMI1640 culture fluid containing 10% calf serum, 37 DEG C, cultivate under the conditions of 5%CO2, trophophase cell Jing trypan blues of taking the logarithm
After dyeing determine viable count more than 95%, collect cell, regulations concentration be 1 × 108/ml, randomly select 2 it is naked little
Mus, every neck side injection cell suspension 0.1ml.The accessible tumor tissues of inoculation position after 10 days, visible diameter 0.5 after 3 weeks～
1cm lumps.Cervical dislocation puts to death nude mouse, takes out tumor tissues, is cut into 1mm × 1mm × 1mm fritters standby.It is naked little by 210
Tumor fritter is delivered to nude mouse neck side with No. 18 anesthetic trocars subcutaneous with etherization by Mus.Sterilization site of puncture skin, gently
Tabletting is carved.Postoperative nude mouse all survives, without obvious adverse reaction.After 9～10 days, tumor starts to grow, tumor formation rate 100%, and 3
With vernier caliper measurement diameter of tumor after week.Start treatment, daily subcutaneous, abdominal cavity difference drug administration by injection is continuous 10 days, matched group
Give same volume normal saline.
Experimental technique
Tumor quality, stereometry：Nude mouse is put to death after last dose 24h, subcutaneous transplantation tumor is extractd, is peeled off its table as far as possible
Bread film, it is with vernier caliper measurement Subcutaneous tumor diameter, public with V=1/2ab2 (a is tumor maximum diameter, and b is tumor most path)
Formula calculates tumor body, and analytical balance is weighed.
A is Arborisidine A, and B is pimelautide.
The gross tumor volume mm3 of each group mice, tumor quality g compare (x ± s),
P<0.05
Test result indicate that：As a result the gross tumor volume mm3 of each group nude mouse, the comparison of tumor quality g, are administered after experiment
Arborisidine A and pimelautide are 16:1-19:The gross tumor volume mm3 of 1 group of nude mouse, tumor quality g's is significantly lower than
There is matched group in other administration groups, mouse survival rate is also higher, it is seen that Arborisidine A and pimelautide are 16:1-
19:There is good effect to the treatment of human gastric cancer nude mouse subcutaneous transplantation tumor between 1, it is obvious for gastric cancer prevention effect.
Claims (3)
1. a kind of pharmaceutical composition for suppressing gastric cancer, it is characterised in that effective ingredient includes Arborisidine A, structure
Formula is as follows：
2. a kind of pharmaceutical composition for suppressing gastric cancer according to claim 1, it is characterised in that effective ingredient is also wrapped
Include pimelautide.
3. a kind of pharmaceutical composition for suppressing gastric cancer according to claim 2, it is characterised in that according to weight meter
Calculate, Arborisidine A and pimelautide ratio are 1:1-20:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611134386.0A CN106540237A (en) | 2016-12-10 | 2016-12-10 | A kind of pharmaceutical composition for suppressing gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611134386.0A CN106540237A (en) | 2016-12-10 | 2016-12-10 | A kind of pharmaceutical composition for suppressing gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106540237A true CN106540237A (en) | 2017-03-29 |
Family
ID=58397458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611134386.0A Withdrawn CN106540237A (en) | 2016-12-10 | 2016-12-10 | A kind of pharmaceutical composition for suppressing gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106540237A (en) |
-
2016
- 2016-12-10 CN CN201611134386.0A patent/CN106540237A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200138771A1 (en) | Anti-tumoural effects of cannabinoid combinations | |
| JP5580409B2 (en) | Composition for injection for topical administration for anti-cancer treatment containing hydroxychloroquine | |
| CN107551254A (en) | A kind of Chinese medicine composition with preventing and treating Colon and rectum precancerous lesion and preparation method and application | |
| CN109081801A (en) | The indoles alcohol derivative of acidic amino acid modification, synthesis, activity and application | |
| CN101361732B (en) | Medicinal preparation containing garcinia acid and use thereof | |
| CN102441168B (en) | Medicine composition containing apigenin, apigenin derivant and Bc1-2 inhibitor and application thereof in preparation of medicines capable of treating cancer | |
| CN102688493B (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
| CN109793740A (en) | Application of the pazopanib hydrochloride in preparation treatment pulmonary fibrosis disease drug | |
| CN103263416A (en) | Application of pyridylamine compound in preparation of drugs used for treating lung cancer and suitable for oral administration | |
| CN107375258A (en) | A kind of antineoplastic combination medicine and its purposes in cancer therapy drug is prepared | |
| CN105380956B (en) | A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application | |
| CN108066339B (en) | A kind of pharmaceutical composition of Parecoxib Sodium | |
| Soares et al. | The combination of Cl-IB-MECA with paclitaxel: A new anti-metastatic therapeutic strategy for melanoma | |
| CN106540237A (en) | A kind of pharmaceutical composition for suppressing gastric cancer | |
| CN107007611A (en) | Application of the nomegestrol acetate in the medicine for preparing treatment carcinoma of endometrium | |
| CN109432086A (en) | The application of qinghaosu or derivatives thereof and the composition of EGFR-TKI targeted drug | |
| WO2019034069A1 (en) | Antitumor combination drug and use thereof in preparation of anticancer drug | |
| CN111265545B (en) | Composition for treating lung tumor | |
| CN104902901A (en) | Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of CBP/catenin | |
| US20190060330A1 (en) | Application of 4-hydroxy salicylanilide in preparation of anti-myeloma or anti-lymphoma drugs | |
| Wang et al. | Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model | |
| CN106714807A (en) | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma | |
| CN102961380A (en) | Pharmaceutical composition for treating acute lung injury | |
| CN116196376B (en) | Traditional Chinese medicine composition for nourishing heart, soothing nerves, strengthening spleen and resolving stagnation and application thereof | |
| CN106727975A (en) | It is a kind of to treat medicine of breast cancer and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170329 |
|
| WW01 | Invention patent application withdrawn after publication |